Investor Presentaiton
Revenue: Major Products in Japan
Daiichi-Sankyo
(Bn JPY)
FY2022 Q1
FY2023 Q1
YOY
Results
Results
Lixiana
anticoagulant
25.1
27.9
+2.8
Pralia
Tarlige
treatment for osteoporosis/ inhibitor of the progression of
bone erosion associated with rheumatoid arthritis
pain treatment
9.9
10.7
+0.8
8.9
11.7
+2.8
Vimpat
anti-epileptic agent
5.3
6.4
+1.1
treatment for bone complications caused by bone
Ranmark
4.9
5.0
+0.0
metastases from tumors
Tenelia
type 2 diabetes mellitus treatment
5.6
5.3
-0.3
anti-cancer agent
Enhertu
2.4
4.4
+1.9
(HER2-directed antibody drug conjugate)
Efient
antiplatelet agent
4.9
6.1
+1.3
Canalia
type 2 diabetes mellitus treatment
4.1
4.1
+0.1
Loxonin
anti-inflammatory analgesic
4.6
4.0
-0.6
Emgality
prophylaxis of migraine attacks
1.4
1.7
+0.3
9View entire presentation